A First-In-Human Study of ARO-033 in Adult Participants
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Healthy Participants
In brief
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-033 compared to placebo in adult normal healthy volunteers (NHVs).
Key facts
- Study ID
- NCT07662096
- Run by
- Arrowhead Pharmaceuticals
- People needed
- 42
- Starts
- 2026-06-25
- Expected to finish
- 2027-07-18
- Last updated by the study team
- 2026-07-22
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Research Site 1 — Auckland, New Zealand (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.